Display options
Cite
Bussing D, Li Z, Li Y, et al. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration. AAPS J. 2021;23(6):116doi: 10.1208/s12248-021-00647-0.
Bussing, D., Li, Z., Li, Y., Chang, H. P., Chang, H. Y., Guo, L., Verma, A., & Shah, D. K. (2021). Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration. The AAPS journal, 23(6), 116. https://doi.org/10.1208/s12248-021-00647-0
Bussing, David, et al. "Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration." The AAPS journal vol. 23,6 (2021): 116. doi: https://doi.org/10.1208/s12248-021-00647-0
Bussing D, Li Z, Li Y, Chang HP, Chang HY, Guo L, Verma A, Shah DK. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration. AAPS J. 2021 Nov 08;23(6):116. doi: 10.1208/s12248-021-00647-0. PMID: 34750690; PMCID: PMC8575492.
Copy Download .nbib Format: NLM
Share it on

AAPS J. 2021 Nov 08;23(6):116. doi: 10.1208/s12248-021-00647-0.

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration.

The AAPS journal

David Bussing, Zhe Li, Yingyi Li, Hsuan-Ping Chang, Hsueh-Yuan Chang, Leiming Guo, Ashwni Verma, Dhaval K Shah

Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 455 Pharmacy Building, Buffalo, New York, 14214-8033, USA.
  2. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 455 Pharmacy Building, Buffalo, New York, 14214-8033, USA. [email protected].

PMID: 34750690 PMCID: PMC8575492 DOI: 10.1208/s12248-021-00647-0

Abstract

The ocular pharmacokinetics (PK) of antibody-based therapies are infrequently studied in mice due to the technical difficulties in working with the small murine eye. This study is the first of its kind to quantitatively measure the PK of variously sized proteins in the plasma, cornea/ICB, vitreous humor, retina, and posterior cup (including choroid) of the mouse and to evaluate the relationship between molecular weight (MW) and antibody biodistribution coefficient (BC) to the eye. Proteins analyzed include trastuzumab (150 kDa), trastuzumab-vc-MMAE (T-vc-MMAE, 155 kDa), F(ab)

© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Keywords: ADC; antibody fragments; monoclonal antibody; mouse; ocular pharmacokinetics

References

  1. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. - PubMed
  2. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476. - PubMed
  3. Bates A, Power CA. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies (Basel). 2019;8(2). - PubMed
  4. Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804. - PubMed
  5. Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers (Basel). 2019;11(3). - PubMed
  6. Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19(2):79–84. - PubMed
  7. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [press release]. U.S. Food and Drug Administration, December 20, 2019. - PubMed
  8. FDA approves new therapy for triple negative breast cancer that has spread, not responded to other treatments [press release]. U.S. Food and Drug Administration, April 22, 2020. - PubMed
  9. Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265–76. - PubMed
  10. Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015–35. - PubMed
  11. Kaufman PL, Alm A, Levin LA, Adler FH. Adler’s physiology of the eye. 11th ed. London, New York: Saunders/Elsevier; 2011. - PubMed
  12. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879–89. - PubMed
  13. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy. 2007;92:86–93. - PubMed
  14. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118(23):5733–40. - PubMed
  15. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405. - PubMed
  16. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29(4):455–63. - PubMed
  17. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4):1167–74. - PubMed
  18. Fraunfelder FT, Fraunfelder FW. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan Ocul Toxicol. 2012;31(3):195–7. - PubMed
  19. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604. - PubMed
  20. Polat O, Inan S, Ozcan S, Dogan M, Kusbeci T, Yavas GF, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017;47(4):205–10. - PubMed
  21. Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213–24. - PubMed
  22. del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111–24. - PubMed
  23. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol. 2008;36(1):49–62. - PubMed
  24. Zernii EY, Baksheeva VE, Iomdina EN, Averina OA, Permyakov SE, Philippov PP, et al. Rabbit models of ocular diseases: new relevance for classical approaches. CNS Neurol Disord Drug Targets. 2016;15(3):267–91. - PubMed
  25. Robinson GC, Jan JE. Acquired ocular visual impairment in children 1960–1989. Am J Dis Child. 1993;147(3):325–8. - PubMed
  26. Robinson GC, Jan JE, Kinnis C. Congenital ocular blindness in children, 1945 to 1984. Am J Dis Child. 1987;141(12):1321–4. - PubMed
  27. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick’s Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res. 2009;37(Database issue):D793-6. - PubMed
  28. Krebs MP, Collin GB, Hicks WL, Yu M, Charette JR, Shi LY, et al. Mouse models of human ocular disease for translational research. PLoS One. 2017;12(8):e0183837. - PubMed
  29. Won J, Shi LY, Hicks W, Wang J, Hurd R, Naggert JK, et al. Mouse model resources for vision research. J Ophthalmol. 2011;2011:391384. - PubMed
  30. Chang B. Mouse models for studies of retinal degeneration and diseases. Methods Mol Biol. 2013;935:27–39. - PubMed
  31. Chang B, Hawes NL, Hurd RE, Wang J, Howell D, Davisson MT, et al. Mouse models of ocular diseases. Vis Neurosci. 2005;22(5):587–93. - PubMed
  32. Herceptin(R). [package insert]. South San Fransisco, CA: Genentech, Inc. 1998. - PubMed
  33. Li Z, Li Y, Chang HP, Chang HY, Guo L, Shah DK. Effect of size on solid tumor disposition of protein therapeutics. Drug Metab Dispos. 2019;47(10):1136–45. - PubMed
  34. Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43(6):567–82. - PubMed
  35. Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells. Drug Metab Dispos. 2020;48(5):368–77. - PubMed
  36. Aerts J, Nys J, Arckens L. A highly reproducible and straightforward method to perform in vivo ocular enucleation in the mouse after eye opening. J Vis Exp. 2014;92:e51936. - PubMed
  37. SimBiology. 6.0 ed. Natick, Massachusetts, United States: The MathWorks, Inc.; 2020. - PubMed
  38. Nedelman JR, Gibiansky E, Lau DT. Applying Bailer’s method for AUC confidence intervals to sparse sampling. Pharm Res. 1995;12(1):124–8. - PubMed
  39. Microsft Excel. Office 365. Redmond, Washington, United States: Microsoft Corporation; 2020. - PubMed
  40. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297–305. - PubMed
  41. Li Z, Krippendorff BF, Sharma S, Walz AC, Lave T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs. 2016;8(1):113–9. - PubMed
  42. Kazemi T, Tahmasebi F, Bayat AA, Mohajer N, Khoshnoodi J, Jeddi-Tehrani M, et al. Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma (Larchmt). 2011;30(4):347–53. - PubMed
  43. Ding X, Gu W, Zhong Y, Hao X, Liu J, Xia S, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020;60:102996. - PubMed
  44. Jakubiak P, Alvarez-Sanchez R, Fueth M, Broders O, Kettenberger H, Stubenrauch K, et al. Ocular pharmacokinetics of intravitreally injected protein therapeutics: comparison among standard-of-care formats. Mol Pharm. 2021;18(6):2208–17. - PubMed
  45. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536–44. - PubMed
  46. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000;17(12):1503–10. - PubMed
  47. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–33. - PubMed
  48. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114(12):2179–82. - PubMed
  49. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855–9. - PubMed
  50. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50(10):4807–13. - PubMed
  51. Gadkar K, Pastuskovas CV, Le Couter JE, Elliott JM, Zhang J, Lee CV, et al. Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics. Invest Ophthalmol Vis Sci. 2015;56(9):5390–400. - PubMed
  52. Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol. 2011;5:697–704. - PubMed
  53. Chang HY, Morrow K, Bonacquisti E, Zhang W, Shah DK. Antibody pharmacokinetics in rat brain determined using microdialysis. MAbs. 2018;10(6):843–53. - PubMed
  54. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32. - PubMed
  55. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248–52. - PubMed

Publication Types

Grant support